Edition:
India

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

113.50GBp
20 Jul 2017
Change (% chg)

-- (--)
Prev Close
113.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,321,483
52-wk High
166.97
52-wk Low
109.50

VEC.L

Chart for VEC.L

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.45
Market Cap(Mil.): £765.62
Shares Outstanding(Mil.): 679.34
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 13.49 17.10
EPS (TTM): -- -- --
ROI: -- -7.23 -5.56
ROE: -- -6.74 -4.84

Vectura signs deal with Novartis for generic U.S. lung therapy

Vectura Group Plc said on Wednesday it has signed an exclusive deal with Sandoz AG, a unit of Swiss drugmaker Novartis, to develop a generic copy of an existing combined lung therapy for the U.S. market.

28 Jun 2017

Vectura signs deal with Novartis for generic U.S. lung therapy

June 28 Vectura Group Plc said on Wednesday it has signed an exclusive deal with Sandoz AG, a unit of Swiss drugmaker Novartis, to develop a generic copy of an existing combined lung therapy for the U.S. market.

28 Jun 2017

BRIEF-Vectura inks new U.S. deals for generic asthma therapy​

* ‍New development and licence agreement for a U.S. inhaled generic​

28 Jun 2017

BRIEF-Vectura says to present positive phase I data for VR942

* Vectura group plc - vr942 positive phase i data to be presented at American Thoracic Society 113th Annual Conference

22 May 2017

BRIEF-Vectura posts 9-month loss before taxation of 40.1 million stg

* Nine-Month pretax loss 40.1 million stg versus loss of 1.9 million stg for 12 months ended March 31, 2016

21 Mar 2017

BRIEF-Vectura achieves 9 mln stg royalty cap from GSK's Ellipta

* Achieves £9 million royalty cap from gsk ellipta ® products Source text for Eikon: Further company coverage: (Reporting By London Bureau)

16 Feb 2017

BRIEF-Vectura gets $5 mln after an inhaling device hits sales milestone

* Seebri/Ultibro Breezhaler 2016 sales reach $512 mln triggering $5 mln milestone receipt Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

25 Jan 2017

BRIEF-Vectura says U.S. FDA approves IND for paediatric asthma trial

* Fda approves IND to support Vectura's wholly-owned programme VR647 in paediatric asthma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

24 Jan 2017

Earnings vs. Estimates